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BACKGROUND AND PURPOSE
Our initial aim was to generate cannabinoid agents that control spasticity, occurring as a consequence of multiple sclerosis (MS),
whilst avoiding the sedative side effects associated with cannabis. VSN16R was synthesized as an anandamide (endocannabinoid)
analogue in an anti-metabolite approach to identify drugs that target spasticity.
EXPERIMENTAL APPROACH
Following the initial chemistry, a variety of biochemical, pharmacological and electrophysiological approaches, using isolated
cells, tissue-based assays and in vivo animal models, were used to demonstrate the activity, efﬁcacy, pharmacokinetics and
mechanism of action of VSN16R. Toxicological and safety studies were performed in animals and humans.
KEY RESULTS
VSN16R had nanomolar activity in tissue-based, functional assays and dose-dependently inhibited spasticity in a mouse experi-
mental encephalomyelitis model of MS. This effect occurred with over 1000-fold therapeutic window, without affecting normal
muscle tone. Efﬁcacy was achieved at plasma levels that are feasible and safe in humans. VSN16R did not bind to known CB1/CB2/
GPPR55 cannabinoid-related receptors in receptor-based assays but acted on a vascular cannabinoid target. This was identiﬁed as
the major neuronal form of the big conductance, calcium-activated potassium (BKCa) channel. Drug-induced opening of
neuronal BKCa channels induced membrane hyperpolarization, limiting excessive neural-excitability and controlling spasticity.
CONCLUSIONS AND IMPLICATIONS
We identiﬁed the neuronal form of the BKCa channel as the target for VSN16R and demonstrated that its activation alleviates
neuronal excitability and spasticity in an experimental model of MS, revealing a novel mechanism to control spasticity. VSN16R is
a potential, safe and selective ligand for controlling neural hyper-excitability in spasticity.
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Abbreviations
BKCa, big conductance calcium-activated potassium channel; Cmax, maximum concentration; EAE, experimental autoim-
mune encephalomyelitis; MS, multiple sclerosis; SAD, single ascending dose
Introduction
Multiple sclerosis (MS) is the major cause of non-traumatic
disability in young adults. Disease induces neurological at-
tacks and nerve damage leading to impaired neurotransmis-
sion and the development of a number of poorly controlled,
troublesome symptoms (Compston and Coles, 2002). Spas-
ticity is a common major debilitating consequence of MS
(Barnes et al., 2003) and is clinically deﬁned as a velocity-
dependent increase in muscle tone resulting from hyper-
excitable stretch reﬂexes, spasms and hypersensitivity to
normally innocuous sensory stimulations (Trompetto et al.,
2014). The intermittent or sustained involuntary muscle
hyperactivity that characterizes spasticity is associated with
upper motor neuron lesions that can be located anywhere
along the path of the corticospinal (pyramidal) tracts from
the brain to the spinal cord (Baker et al., 2012; Trompetto
et al., 2014). Whilst the aetiology of spasticity in MS has been
relatively little studied, this contrasts to experimental spastic-
ity caused by spinal cord injury, where persistent inward so-
dium and calcium currents and changes in chloride ion
balance in motor neurons and increases in the number of pri-
mary afferent projections to the motor nerves are believed to
be the key mechanisms mediating spasticity (Li et al., 2004;
Toda et al., 2014; Trompetto et al., 2014). Clinically, these
are currently treated using either nerve blocking procedures
or pharmacological agents, such as depolarizing-ion channel
inhibitors, GABAA and GABAB receptor agonists,
α2-adrenoceptor agonists, dantrolenewithin the muscle,
and more recently nabiximols (medical cannabis) to target
the cannabinoid CB1 receptor in the periphery and CNS
(Baker et al., 2000; Shakespeare et al., 2003; Novotna et al.,
2011; Baker et al., 2012; Pryce et al., 2014). Whilst these phar-
macological treatments are active, their use is associated with
dose-limiting side effects that limit compliance and early
adoption following the development of spasticity. (Shakespeare
et al., 2003; Novotna et al., 2011; Baker et al., 2012).
We have established a relapsing progressive experimen-
tal autoimmune encephalomyelitis (EAE) model of MS in
ABH mice as a system for studying spasticity (Baker et al.,
2000; 2012). This model responds to standard spasticity
therapies (Baker et al., 2012; Hilliard et al., 2012) and was
utilized to provide the initial experimental demonstration
that cannabis and the endocannabinoid system could con-
trol spasticity (Baker et al., 2012; Hilliard et al., 2012). The
endocannabinoid signalling pathway is part of a much
wider lipid signalling system with pleiotropic actions in
the CNS, cardiovascular and immune systems (Howlett
et al., 2002). Anandamide is one of the key endogenous
endocannabinoid mediators, and a close analogue,
methanandamide, can inhibit spasticity in EAE (Baker
et al., 2000). As anandamide is rapidly degraded in vivo
(Howlett et al., 2002), by using an anti-metabolite approach
to create a more stable, drug-like molecule with a good po-
tential to interfere with cannabinoid signalling and avoid
brain-mediated side effects, we synthesized a series of
monocyclic alkyl amides (Hoi et al., 2007) based on
constrained conformations of anandamide (Berglund et al.,
2000; Supporting Information Figure S1). We found that
one compound 3-(6-(dimethylamino)-6-oxohex-1-enyl)-N-
(1-hydroxypropan-2-yl)benzamide, (VSN16; Hoi et al.,
2007) has potent activity in tissue-based cannabinoid recep-
tor assays yet was active in CB1 receptor deﬁcient mice,
pointing to a new target. We identiﬁed the neuronal form of
the big conductance calcium-activated potassium channel
(BKCa) as the target for VSN16 and demonstrated that its
activation alleviates neuronal excitability and spasticity in
an experimental model of MS.
Methods
Animals
Adult Biozzi male and female ABH mice were from stock bred
either at the Institute of Neurology (ION) or QueenMary Uni-
versity of London (QMUL) or were purchased fromHarlan UK
(Bicester, UK). Congenic-ABH CB1 receptor (Pryce et al., 2003)
or G-protein 55 receptor (GPR55)-deﬁcient mice (Sisay
et al., 2013) were from stock bred either at ION or QMUL.
Outbred mice and rats were purchased from Charles Rivers
(Margate, UK) or Harlan UK. Animal work was performed
following an ethical review by the Local Animal Welfare
and Ethical Review Bodies and the UK Government Home
Ofﬁce. Animal experiments were performed under the Ani-
mals (Scientiﬁc Procedures) Act 1986 and European Union
Directives 86/609/EEC and EU 2010/63/EU. Animal housing
and other elements related to documenting protocols of
in vivo experiments were as reported previously (Al-Izki
et al., 2012). Animal studies are reported in compliance with
the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and
Lilley, 2015).
Humans
Healthy volunteers were enrolled in a double-blind, placebo-
controlled Phase I safety study, (EudraCT 2013-002765-18)
following ethical review of the project (Ofﬁce of Research
Ethics Northern Ireland) and informed consent was obtained
that complied with the Declaration of Helsinki, GCP (CPMP/
ICH/135/95) and local regulation. At the time of designing
the study, reproductive toxicity had not been completed.
Therefore for safety reasons and ease of recruitment, only
males were studied. Individuals were screened negative for
amphetamine, ecstasy, benzodiazepines, ethanol, metha-
done metabolites, cannabinoids, barbiturates, cocaine, urine
creatinine, opiates, cotinine and tricyclic anti-depressants.
Individuals were randomized to receive either 25, 50, 100,
200, 400 or 800 mg (n = 6 per group) formulated VSN16R or
placebo capsules (n = 2 per group) as part of a single ascending
dose study, or multiple ascending dose study with twice a day
25, 100 and 400 mg VSN16R for 1 week (n = 6 per group). A
randomization schedule was provided to the pharmacist,
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but study personnel were blinded to this. These people fasted
before dosing, except one group that were fed a standardized
high fat breakfast within 0.5 h prior to dosing (n = 6). Serial
plasma samples using EDTA anti-coagulant were collected.
This study was performed by Quintiles Limited, London,
UK. The sample size was based on experience from previous
similar Phase 1 studies with other compounds to obtain
adequate safety, tolerability and pharmacokinetics data to
achieve the objectives of the study while limiting the expo-
sure of fewer subjects to drugs and procedures.
Toxicology
Twenty-eight day toxicology in rats and dogs for Investiga-
tional New Drug ﬁling was performed by Charles Rivers
(UK). Reproductive toxicology in rabbits was performed by
Charles Rivers (Canada). Pharmacokinetic and/or toxicologi-
cal doses ranged from 5 to 1000 mg·kg1 p.o. in Sprague
Dawley male and female rats (n = 6-26 per group),
50–200 mg·kg1 p.o. in male and female Beagle dogs (n = 6
per group) and 100–750 mg·kg1 p.o. in female New
Zealand white rabbits (n = 9 per group). Results are expressed
as mean ± SD. The sample size was based on experience from
previous similar toxicology studies with other compounds to
obtain adequate safety, tolerability and pharmacokinetics
data to achieve the objectives of the study.
Electrically-evoked contraction of the mouse
vas deferens
Vasa deferentia were obtained from outbred MF-1 mice and
mounted vertically in a 4 mL organ bath at an initial tension
of 0.5 g. The baths contained Mg2+-free Krebs solution (NaCl
118.2 mM, KCl 4.75 mM, KH2PO4 1.19 mM, NaHCO3
25.0 mM, glucose 11.0 mM and CaCl2·6H2O 2.54 mM),
which was kept at 35–36°C and bubbled with 95% O2 and
5% CO2. Isometric contractions were evoked by stimulation
with 0.5 s trains of three pulses of 110% maximal voltage
(train frequency 0.1 Hz; pulse duration 0.5 ms) through a
platinum electrode attached to the upper end and a stainless
steel electrode attached to the lower end of each bath (Ross
et al., 2001). Contractions were monitored by a computer
using a data recording and analysis system as described previ-
ously (Ross et al., 2001). After placement in an organ bath,
each tissue was subjected to a stimulation-free period of
10 min and then stimulated for 10 min. Tissues were then
subjected to alternate periods of stimulation (5 min) and rest
(10 min) until consistent twitch amplitudes were obtained.
This equilibration procedure was followed by a stimulation-
free period of 25 min. Tissues were then stimulated for
5 min after which the ﬁrst agonist addition was made and
stimulation continued until the end of the experiment.
Receptor binding
Receptor binding/agonism activity of 10 μM VSN16R, plus
positive controls, was performed on cell lines transfected with
human cannabinoid CNR1 and CNR2 and large number of
other receptors and transporters and was performed by Cerep
SA, (Poitiers, France); Chantest Inc. (Cleveland Ohio),
DiscoveRx (Birmingham, UK); Multispan Inc., (Hayward, CA,
USA); and MDS Pharma services (Taipei, Taiwan).
Methoxamine-evoked contraction of rat
mesenteric artery
Adult male Wistar rats (200–350 g) were killed by cervical
dislocation and the third-order branches of the superior
mesenteric artery, which provides the blood supply to the
intestine, were removed and cleaned of adherent tissue.
Segments (2 mm in length) were mounted in a
Mulvany–Halpern-type wire myograph (Model 610 M;
Danish Myo Technology, Aarhus, Denmark) and maintained
at 37°C in gassed (95% O2/5% CO2) Krebs–Henseleit solu-
tion of the following composition (mM): 118 NaCl,
4.7 KCl, 1.2 MgSO4, 1.2 KH2PO4, 25 NaHCO3, 2 CaCl2
and 10 D-glucose, as previously described (Ho and Randall,
2007). Vessels were equilibrated and set to a basal tension
of 2 to 2.5 mN. The integrity of the endothelium was
assessed by pre-contracting the vessel with 10 μM
methoxamine (an α1-adrenoceptor agonist), followed by
relaxation with 10 μM carbachol (a muscarinic acetylcho-
line receptor agonist); vessels showing relaxations of
greater than 90% were designated as endothelium-intact.
When the endothelium was not required, it was removed
by rubbing the intima with a human hair; carbachol-
induced relaxation of less than 10% indicated successful
removal. After the test for endothelial integrity, vessels
were left for 30 min and then pre-contracted with 10 μM
methoxamine. This was followed by construction of a
cumulative concentration–relaxation curve to VSN16R
(10 nM–1 μM). To investigate the relaxation mechanisms
of VSN16R, calcium-activated, potassium channel
blockers (apamin, charybdotoxin or iberiotoxin) were
incubated with the vessels either alone or in combination
before construction of the concentration–response curves
to VSN16R. The tension generated by methoxamine in con-
trol vessels was 9.4 ± 0.6 mN, as compared with
10.4 ± 2.5 mN in endothelium-denuded vessels, or
10.5 ± 0.5 mN in the presence of calcium-activated, potas-
sium channel inhibitors. Most experiments were performed
in matched vessels; effects of blockers or endothelial re-
moval were compared with the control responses obtained
in separate vessels of the same rats. All relaxant responses
are expressed as percentage relaxation of the tone induced
by methoxamine. Values are given as mean ± SEM. Statisti-
cal comparisons of concentration-dependent responses were
made by two-way ANOVA using Prism 4 (GraphPad Soft-
ware, Inc, San Diego, CA, USA).
Patch clamp of calcium-activated potassium
channels recording in human cells
The human EA.hy926 endothelial cells (ATCC, Manassas,
USA) were grown in DMEM containing 10% FCS and 1%
HAT (5 mM hypoxanthine, 20 μM aminopterin and
0.8 mM thymidine) and were maintained in an incubator
at 37°C in 5% CO2 atmosphere (Bondarenko et al., 2013).
Human HNC-2 neuronal cells were obtained from ATCC.
For experiments, cells were plated on glass coverslips.
Single-channel recordings were obtained from excised
inside-out membrane patches in symmetrical solutions
using the patch-clamp technique. All patch-clamp experi-
ments were performed at room temperature with the use
of a water hydraulic micromanipulator (WR-6, Narishige,
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Japan). Patch pipettes were pulled from glass capillaries
using a Narishige puller (Narishige Co. Ltd, Tokyo, Japan)
that was ﬁre polished and had a resistance of 3–5 MΩ for
whole-cell recordings and 5–7 MΩ for single-channel re-
cordings. The pipettes were ﬁlled with 140 mM KCl,
10 mM HEPES, 1 mM MgCl2, 5 mM EGTA and 4.9 M CaCl2
buffered to pH 7.2 by adding KOH. Cells were super-
perfused with a bath solution containing 140 mM NaCl,
5 mM KCl, 1.2 mM MgCl2, 10 mM HEPES, 10 mM glucose
and 2.4 mM CaCl2. Following gigaseal formation, bath so-
lution was switched to the following: 140 mM KCl,
10 mM HEPES, 1 mM MgCl2, 5 mM EGTA and a designated
free Ca2+ concentration, which was adjusted by adding dif-
ferent amounts of CaCl2 buffered to pH 7.2. (Bondarenko
et al., 2011; Bondarenko et al., 2013). Single-channel activ-
ity was expressed as NPo, where N represents the number
of functional ion channels in the membrane patch and
Po represents the open channel probability determined
from idealized traces (Bondarenko et al., 2011). NPo was
obtained from ≥20 s of continuous recording under each
experimental condition. The effect of VSN16R was esti-
mated after 3 min of continuous exposure to VSN16R-
containing solution. Data were analysed by ANOVA, and
statistical signiﬁcance was evaluated using Scheffés post
hoc test of the Prism 5 software for Windows (GraphPad
Software).
Pharmacokinetics
The stability of compounds when subjected to hepatic and
plasma degradation was assessed in vitro by Inpharmatica,
Cambridge, UK. Compounds (1 μM) were incubated with
either pooled mouse liver microsomes (0.1 mg protein
mL1) or pooled mouse plasma at 37°C for 0, 5, 10, 20 and
40 min before termination with acetonitrile containing war-
farin as an analytical internal standard. Samples were centri-
fuged, and the resultant supernatant analysed for parent
compound. The mass responses at baseline were taken as
the 100% reference values against which the disappearance
of the compound was measured. The natural log of the % re-
maining values was used to generate linear plots of disappear-
ance of the compounds. Half-life values were calculated from
the slope of these plots. Hepatocyte metabolism was assessed
by Cyprotex, Macclesﬁeld, and 10 μMVSN16R was incubated
with primary mouse, rat, monkey (Macaque) and human he-
patocytes for 1 h, and the presence of metabolites was
assessed using liquid crystallography mass spectroscopy. The
stability of VSN16R was assessed in vivo by Inpharmatica,
Cyprotex and Charles Rivers, Cambridge. Blood (plasma)
samples were obtained prior to and 5 min to 24 h after drug
administration of 2–5 mg·kg1 i.v. or 5 mg·kg1 p.o. VSN16R
into outbred mice and rats (n = 3 per time point). In addition,
plasma, brain and spinal cord samples were obtained from
ABH with spastic EAE. Immediately after blood collection,
the brain and spinal cord were removed and then stored at
20°C prior to assay. Tissue samples were weighed, homoge-
nized and centrifuged, and the lysates generated. Brain ly-
sates and plasma were assayed by LC–MS methods by
Inpharmatica/Charles Rivers, Cambridge, UK. This was also
performed using aWaters Xevo TQ or API4000, AB Sciexmass
spectrometer using spiked samples as standards. PK Solutions
Software (Summit Research Services, Montrose, CO, USA), AB
Sciex Analyst software combined with Thermo Fisher Scien-
tiﬁc Watson LIMS processing and reporting software or
WinNonLin pharmacokinetic or PK solutions 2.0 software
(Summit Research Services, Montrose CO, USA) were used to
produce PK parameters. Data are expressed as mean ± SEM.
The detection limit of VSN16R was 2 ng·mL1 in plasma
and brain and 14 ng·mL1 in spinal cords. The detection limit
of VSN22R was 2 ng·mL1 in plasma and 0.1 ng·mL1 for
VSN44R in plasma. Pharmacokinetics in toxicological sam-
ples in rats (n = 6 per group), dogs (n = 6 per group) and
humans (n = 6 per group) were performed by Charles Rivers
(Edinburgh, UK).
Open-field activity monitoring
Motor activity was assessed using 27.9 × 27.9 cm open ﬁeld
activity monitor chambers and computer software (Med
Associates Inc, St. Albans, VT, USA.). This was typically per-
formed in a darkened room. Recordings were initiated once
the mouse entered the chamber and continued for 5 min.
These chambers, allowing four simultaneous recordings of in-
dividual mice and were ﬁtted with infrared beams that could
detect movement in the X, Y planes. The total distance trav-
elled (cm) was recorded. Results are expressed as mean ± SEM.
These were analysed by Student’s paired t-test or a one-way
ANOVA with Bonferroni post hoc test, using SigmaStat
V3/Sigmaplot V9 or V11 software (Systat Ltd Hounslow, UK.
Al-Izki et al., 2012).
Temperature testing
Temperature of animals was monitored by using a thermo-
couple placed under the hindlimb, and the temperature was
allowed to equilibrate and was recorded once it failed to
increase further (Pryce et al., 2014). These recordings were
assessed 20 min following administration of compounds.
Results are expressed as mean ± SEM, and were analysed by
Student’s t-test or a one-way ANOVA with Bonferroni post
hoc test using Sigma/StatV3/Sigmpaplot V9 or V11 software
(Pryce et al., 2014).
Induction of spasticity
Disease was induced in ABH mice by immunization with
spinal cord homogenate in Freunds adjuvant as described
previously and included data relevant to the ARRIVE guide-
lines related to EAE induction (Al-Izki et al., 2012; Pryce
et al., 2014). Following the development of chronic relaps-
ing EAE, spasticity typically developed after two to three
relapses, about 80–100 days post-induction onwards as a
consequence of the accumulation of nerve damage (Baker
et al., 2000; Al-Izki et al., 2012). This was assessed in non-
anaesthetized, awake animals during remission from active
paralytic episodes by the force required to bend the hind
limb to full ﬂexion against a custom-built strain gauge, fol-
lowing extension of the limb prior to measurement. This
cannot be used on limbs that are ﬂexed, which were not
measured. Animals with visible spasticity were used as spas-
ticity became apparent. The data were analysed using Spike
2 software (Cambridge Electronic Design, UK), and a mean
score for each limb at each time point was calculated, and
forces were converted to Newtons (Baker et al., 2000; Pryce
et al., 2014). Animals were entered into the study following
the development of visible spasticity. These mice were
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randomly assigned to treatment group by the person ad-
ministering the compounds or vehicle, and mice were
assessed in a blinded fashion by a different assessor. Data
were analysed blinded to treatment. Each group contained
a minimum of ﬁve different animals. This would provide
80% power to detect a 25% change in limb (n = 10) stiff-
ness at the P < 0.05 level, as reported previously (Pryce
et al., 2014). The results represent the mean ± SEM
resistance to ﬂexion force (N) or individual limbs, which
were compared using one-way repeated measures ANOVA
incorporating a Student–Newman–Keuls post hoc test or in-
frequently paired t-tests using SigmaStat V3/Sigmaplot V9
or V11 software (Pryce et al., 2014). Resistance forces of
limbs below 0.15 N were typically excluded from analysis,
as this is below the normal range on non-spastic limbs
(Baker et al., 2000) consistent with a pre-deﬁned protocol.
Differences were compared with baseline using repeated
measures ANOVA rather than comparison of group means,
because there was such marked differences in the severity
of spasticity in individual limbs, resulting in variable
baseline group means, as shown previously (Baker et al.,
2000). Therefore, to assist in comparison, data were
sometimes also expressed as percentage change ± SEM from
baseline.
Electrophysiology
Animals with spasticity were anaesthetized using 50 mg·kg1
ketamine (Modol et al., 2014) and 1 mg·kg1
dexmedetomidine/medetomidine according to veterinary
advice. The experiment was terminated, without recovery,
while the animals were still anaesthetized. A drop of 2%
hyroxypropyl methylcellulose was added to the eyes to keep
them moist. The animal was secured in a stereotactic frame,
and body temperature was maintained at 37°C with a small
heating plate with a built-in resistance temperature detector
sensor connected to a direct current temperature controller
linked to an anal thermocouple. The legs and nape of the
neck were shaved, and the sciatic nerve in the upper thigh
was surgically exposed. The animal, at the nape of the neck,
and heating pads were earthed using electrodes. The animal
was covered to conserve heat. The stimulating electrode was
placed under the sciatic nerve and sealed with white petro-
leum jelly. Stimuli of 100 ms duration constant current were
delivered to the sciatic nerve using a Neurolog NL800
(Digitimer), at a rate of 0.2 Hz, and the current increased until
a convincing recording of both M-wave (stimulus from elec-
trode to muscle) and H-wave (stimulus from the electrode to
the spinal reﬂex arc and frommotor nerves to muscle approx-
imately 7 ms after the M wave (Modol et al., 2014) were gen-
erated in each sweep). The current required varied from
preparation to preparation but was substantially less than
that needed to elicit supramaximal nerve activation (current
range ≈1 mA; Modol et al., 2014) Differential motor unit re-
cording from anterior tibialis was achieved using a Neurolog
AC preampliﬁer and headstage (Digitimer, Welwyn Garden
City, UK). Two monopolar 25 gauge needle recording elec-
trodes were inserted into the muscle at either end, the signal
was ampliﬁed, band-pass ﬁltered between 200 Hz and
1 KHz, digitized by a 1401 plus interface (at 3 KHz) and then
displayed and saved by a computer running Signal software
(Cambridge Electronic Design). VSN16R 30 mg·kg1 or
0.1 mL PBS was injected i.v. via the tail vein. This route was se-
lected as it could be administered without further movement
of the animal or disturbance of the recording electrodes. The
high starting dose was selected based on the amount of
VSN16R that could easily be dissolved in saline to maximize
duration, as a starting point. The response was recorded for
12 min, although once detected the H response was
maintained without attenuation for over a 30 min. The
amplitude (mV) was measured and compared with that at
the time of injection, taken as 100%, rather than a mean re-
sponse, due to variability in the current required to elicit
the maximal H response.
RNA extraction and sequencing
Three EAE mice demonstrating spasticity and three age-
matched control mice were killed, and the spinal cord tissue
was removed, snap-frozen and stored at 80°C. These sam-
ples were analysed by RNAseq as described previously
(Sevastou et al., 2016). Frozen tissue was disrupted in TRIzol®
Reagent on ice, using a rotor-stator homogenizer. Following
5 min incubation at room temperature, chloroform was
added to the samples, which were shaken, left to rest and
then centrifuged at 12 000 g for 15 min. The resulting upper
aqueous phase was washed with 70% ethanol, mixed well
and loaded on an RNeasy column. Thereafter, the Qiagen
RNeasy®Mini Kit protocol was followed to extract and purify
mRNA. The mRNA integrity was assessed by microﬂuidic cap-
illary electrophoresis using the Agilent 2100 Bioanalyzer. All
samples had a 260/280 ratio > 1.8 with RNA integrity
number > 9. RNA sequencing was performed at the UCL
Genomics facility (UCL Institute of Child Health, London)
using the Illumina NextSeq 500 platform. The FASTQ ﬁles
generated for each sample were aligned to the UCSC Mus
musculus HG19 reference genome using the TopHat2 soft-
ware (Illumina). Downstream analysis of these alignments
was performed using Cufﬂinks software (Illumina). Cufﬂinks
computes normalized fragments per kilobase of exon per mil-
lion fragments mapped, which reﬂect the expression levels of
each mRNAmolecule. The readings were mapped to a total of
23 352 genes and 30 608 transcripts. The statistical analysis
resulted in P values corrected for multiple testing with a
default false discovery rate of q < 0.05 (Sevastou et al., 2016).
Western blotting
Mouse spinal cord whole tissue was homogenized in RIPA
buffer (150 mM NaCl, 1.0% IGEPAL CA-630, 0.5% sodium
deoxycholate, 0.1% SDS and 50 mM Tris at pH 8.0), supple-
mented with protease and phosphatase inhibitors (Sigma,
Poole, Dorset). Similarly, EA.hy926 cells were lysed in RIPA
buffer supplemented with protease and phosphatase inhibi-
tors. The proteins were resolved on SDS-PAGE and transferred
onto Immobilon-P-PVDF membranes. Membranes were
washed, blocked for 1 h in blocking buffer (5% non-fat dried
milk) and incubated in blocking buffer with primary anti-
body using rabbit polyclonal antibodies against
mouse/human KCNMA1 (APC-021, previously validated by
lack of activity in big conductance calcium-activated potas-
sium channel Kcnma1-deﬁcient mice and APC-151 antibody)
and KCNMB4 (APC-061 antibody, previously validated by
lack of activity in Kcnmb4-deﬁcient mice despite detecting
multiple isoforms), which were purchased from Alomone
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Labs, Jerusalem Israel, whose website reports supporting liter-
ature concerning characterization of the antibodies. These
were incubated overnight at 4°C at 1:200 dilution or mouse
monoclonal antibodies incubated for 2 h at room tempera-
ture (anti-β-actin 1:2000, Santa Cruz BioTech sc-101663).
After repeated washes in Tris buffered saline with Tween 20
(T-TBS; 10 mm Tris–HCl, 150 mm NaCl and 0.5% Tween 20,
pH 7.4), membranes were incubated with horseradish
peroxidase-conjugated secondary antibody (anti-rabbit
immunoglobulins 1:4000, Santa Cruz BioTech sc-2004 or anti-
mouse immunoglobulins 1:1000, ThermoFisher. SA1-100) in
T-TBS for 1 h. Blots were developed by enhanced chemilumi-
nescence detection.
Data and statistical analysis
The data and statistical analysis comply with the recommen-
dations on experimental design and analysis in pharmacol-
ogy (Curtis et al., 2015). Most experiments contained a
minimum of 5 animals or individual samples, consistent with
sample size calculations and experience from previous stud-
ies, as indicated. Group sizes of less than n = 5 were used in
some pharmacokinetic studies, based on a minimum num-
bers approach. However, rodent pharmacokinetic studies
were replicated in additional experiments. The statistical tests
used are reported in the methodological subsections. If this
involved parametric analysis, this included analysis of nor-
mality and equality of variance. The level of probability
deemed to constitute the threshold for statistical signiﬁcance
was P < 0.05.
Chemicals
The production and synthesis of VSN16 (318 Da) and the
VSN16R and VSN16S enantiomers and VSN22 were as
described previously (Hoi et al., 2007). VSN44 was also
synthesized (Supporting Information Methods S1). These
compounds were additionally synthesized to either Good
Manufacturing Practice or Good Laboratories Practice Stan-
dards by Sygnature Chemical Services (Nottingham, UK),
Park Place Research (Cardiff, UK) or Dalton Chemical Labora-
tories Inc. (Toronto, Canada). VSN16R for human use was
formulated in 25 and 100 mg gelatin capsules by Dalton
Chemical Laboratories. R(+)WIN55-212was purchased from
Tocris Ltd. (Bristol, UK) and ±baclofen was purchased from
Sigma Aldrich Ltd (Poole, UK). 10, 10-dimethylheptyl-M8-tet-
rahydrocannabinol-11-oic acid (CT3) was supplied by
Atlantic Ventures Inc. (New York, USA) (Pryce et al., 2014).
BMS-204352; NS-1619, NS-11021, paxilline and CNQX
were purchased from Tocris Ltd or Sigma (Poole, UK). Com-
pounds were dissolved in water; saline or DMSO (WIN55-
212) or ethanol prior to dilution with cremaphor (Sigma)
and PBS (1:1:18). These drugs were delivered via the p.o., i.
p. or i.v. routes at less than 5 mL·kg1, typically 0.1 mL in
mice and 0.5 mL in rats. Although VSN16R is water soluble
(>30mg·mL1), for higher concentrations (200 mg·mL1), it
was dissolved in 20% polypropylene in water.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are
hyperlinked to corresponding entries in http://www.
guidetopharmacology.org, the common portal for data
from the IUPHAR/BPS Guide to PHARMACOLOGY
(Southan et al., 2016), and are permanently archived in the
Concise Guide to PHARMACOLOGY 2015/16 (Alexander
et al., 2015a,b,c,d).
Results
VSN16 is a novel anti-spastic agent
Following the synthesis of VSN16, the afﬁnity of VSN16 (ra-
cemate) for the CB1 receptor was ﬁrst assessed by measuring
the relaxation of electrically-evoked contractions of the vas
deferens (Ross et al., 2001) This is a standard, tissue-based as-
say used to detect cannabinoid receptor activity (Ross et al.,
2001) but assesses autonomic neurotransmission for a wide
range of receptors, via actions on nerves originating from pel-
vic and lumbar/sacral ganglia (Burnstock and Verkhratsky,
2010). VSN16 exhibited potent inhibitory activity with an
EC50 in the low nM (~10 nM) range (Figure 1A). This com-
pared favourably with the potent CB1/CB2 receptor agonist
R(+)WIN55–212 (Figure 1B), although the slope of the
VSN16 dose–response curve (Figure 1A) appeared to be differ-
ent, possibly suggesting activity at a distinct target or targets.
VSN16R did not affect β γ, methylene ATP-induced contrac-
tions in electrically unstimulated vasa deferentia (Supporting
Information Figure S2), indicating that the action of VSN16R
was not directly on the muscle. Although VSN16 was at least
as potent as R(+)WIN55-212 (Figure 1A, B), it failed to induce
visible signs of sedation at 1 mg·kg1 i.v. and did not induce
hypomotility (Figure 1C) or hypothermia (Figure 1D, which
are indicative of central cannabimimetic effects in rodents
(Varvel et al., 2005). This contrasts to the signiﬁcant sedative
effects induced by R(+)WIN55-212 (Figure 1C, D), which are
absent in CB1 receptor-deﬁcit mice (Pryce et al., 2014). Whilst
the action of VSN16 could be antagonized following pretreat-
ment of the vas deferens with SR141716A, a CB1 receptor
antagonist (Figure 1A), when VSN16 was injected directly
into the CNS, it also failed to induce cannabimimetic effects
(Figure 1D), clearly indicating that VSN16 was neither a
global nor a CNS-excluded CB1 receptor agonist in vivo at
the doses tested, and thus was mediating its effects by an-
other SR141716A-sensitive mechanism.
In MS, spasticity is measured via subjective assessments
that are either physician-assessed, such as the modiﬁed
Ashworth Scale, or patient-assessed numerical rating scales
(Shakespeare et al., 2003; Novotna et al., 2011; Wininger
et al., 2015). These are limited compared with objective
measures and may be poorly responsive to treatments
(Shakespeare et al., 2003; Novotna et al., 2011; Wininger
et al., 2015). Although spasticity in mice was visually evident,
it was objectively and quantitatively measured using a strain
gauge to detect limb stiffness (Baker et al., 2000). Interest-
ingly, it was found that 1 mg·kg1 i.v. VSN16 could
signiﬁcantly inhibit spasticity within a few minutes of
administration (Figure 1E) and occurred in the absence of
sedative effects (Figure 1C, D). As VSN16 is chiral, both the
R and S enantiomers were made and VSN16R (EC50 = 10 nM)
was slightly more active than VSN16S (EC50 = 37 nM) in the
mouse vas deferens assay, as was also subsequently seen in
the vasorelaxation of rat mesenteric arteries, which is another
standard tissue-based assay used to measure vascular
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Figure 1
VSN16 inhibits spasticity without sedation. (A, B) Inhibition of electrically evoked contraction of the mouse vas deferens following incubation with
various doses of (A) VSN16 with or without pre-incubation of 31.6 nM SR141617A, (B) R(+)WIN55,212; n = 5–6 replicates. (C, D) Lack of sedative
effect of 1 mg·kg1 VSN16 in ABHmice compared with 1 mg·kg1 R(+)WIN55,212 (n = 5) or 5 mg·kg1 i.v. baclofen (n = 4). The results represent
the mean ± SEM. (C) Hypomotility in a 27 × 27 cm open ﬁeld chamber 30 min after i.v. drug administration and (D) hypothermia 20 min after
drug administration, via the i.v. or intracerebral (i.c.) route, in wild-type ABHmice or CB1 receptor-deﬁcient mice (n = 4 animals per group) except
baclofen (n = 10 animals).(E) Inhibition of spasticity measured as the resistance to hindlimb ﬂexion against a strain gauge in visibly spastic ABH
mice, showing mean ± SEM following injection of 1 mg·kg1 i.v. VSN16 racemate; n = 6 animals, n = 9 limbs. *Signiﬁcantly different compared
with baseline. VSN16 structure in the inset with chiral centre (#) indicated. (F) Pharmacokinetics of VSN16R in outbred mice and rats following
i.v. or p.o. administration. Data represent mean ± SEM; n = 3 male animals per group. (G, H) Inhibition of spasticity measured as the resistance
to hindlimb ﬂexion against a strain gauge in visibly spastic ABH mice; (G) 5 mg·kg1 i.v. VSN16R (n = 7 animals, n = 14 limbs) or VSN16S
(n = 7 animals, n = 13 limbs). (H) The % change in resistance to hindlimb ﬂexion from baseline following vehicle (n = 8 animals, n = 14 limbs),
5 mg·kg1 i.v. VSN16R (n = 7 animals, n = 14 limbs), 5 mg·kg1 i.v. baclofen (n = 6 animals, n = 10 limbs) or 5 mg·kg1 i.v. (n = 8 animals,
n = 13 limbs) or 10 mg·kg1 i.v. (n = 6 animals, n = 11 limbs) using botanical drug substances within medicinal cannabis (Hilliard et al., 2012).
These were undertaken as separate experiments. *Signiﬁcantly different compared with baseline.
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cannabinoid receptor activity (VSN16R EC50 = 110 nM,
VSN16S = 140 nM; Hoi et al., 2007). However, when the in vivo
pharmacokinetic responses were assessed in both outbred
mice and rats (Figure 1F), the clearance of VSN16R adminis-
tered via the i.v. route was relatively fast (half-life of
7–11 min). This demonstrated CNS penetration with a
plasma : brain ratio at maximum concentration (Cmax) of
0.16 in healthy mice (Figure 1E). It was found that VSN16R
appeared slightly more active than VSN16S in spasticity
when tested at 5 mg·kg1 i.v. (Figure 1G) and, therefore, sub-
sequent studies focused on VSN16R. VSN16R 5 mg·kg1 i.v.
could induce comparable inhibition of spasticity to that of
5mg·kg1 i.v. baclofen (Figure 1H), although this dose of bac-
lofen was associated with signiﬁcant sedation (Figure 1C, D).
Likewise, VSN16R appeared to be as potent as 5–10mg·kg1
i.v. (sedative) doses of the botanical drug substances in
nabiximols/medicinal cannabis (Figure 1H; Hilliard et al.,
2012). Therefore, while VSN16Rmay be no more potent than
current anti-spastic agents, it lacked their sedative effects,
which limits compliance and early use in spasticity in MS.
VSN16R is an orally active, anti-spastic agent
In contrast to the i.v. route, the delivery of 5mg·kg1 via the p.
o route showed a longer elimination half-life in rodents
[89 min in mice and 43 min in rats (Figure 1E)]. Oral absorp-
tion was rapid, and Cmax was detected within 15min from ad-
ministration in mice indicating good absorption from the
gastrointestinal tract, and good p.o. bioavailability (22–40%
mouse-rat, respectively, after 5 mg·kg1 p.o.) was evident
(Figure 1F). Doses of up to 30 mg·kg1 i.v. VSN16R in PBS
failed to show any visible evidence of sedation in mice (n = 5
animals), and repeated daily treatment of 1 g·kg1 p.o. in
water to mice for 5 days failed to show any overt behavioural
effects or toxicity and no drug-induced weight loss
(29.0 ± 2.0 g vs. 30.2 ± 1.1, n = 3 mice). Oral VSN16R was also
very-well tolerated in rats, and behavioural testing of rats
treated with 120 mg·kg1 p.o. (n = 6) did not display any ad-
verse behavioural responses in Irwin tests (Roux et al., 2005),
which assesses over 30 largely, neurological and movement,
behavioural outcomes (Supporting Information Table S1).
The effect of p.o. VSN16R on spasticity was analysed in
ABH mice with EAE (Figure 2). Whilst 0.5 mg·kg1 p.o.
VSN16R failed to produce rapidmuscular relaxation and inhi-
bition of spasticity (Figure 2A), signiﬁcant therapeutic activ-
ity was evident within 10 min following administration of
1 mg·kg1 and 5 mg·kg1 VSN16R p.o. (Figure 2A). Therefore,
VSN16R has over 1000-fold therapeutic window. Despite the
marked variability in spasticity in individual limbs (Figure 2B),
which could inﬂuence group means depending on which an-
imals were assessed (Figure 2C, D), it was evident that most
limbs showed a signiﬁcant level of relaxation irrespective of
the degree of initial spasticity when treated with 5 mg·kg1
p.o. VSN16R (n = 17 animals, 32 = limbs; Figure 2B). The
duration of activity was dose-dependent, and inhibition of
spasticity lasted for over 6 h following a single dose of
40 mg·kg1 p.o. (Figure 2C). Furthermore, the therapeutic
effect was sustained after repeated daily administration of
40 mg·kg1 VSN16R p.o. for 7 days (Figure 2D). This
suggested a lack of signiﬁcant receptor desensitization
and even some cumulative beneﬁt, as following repeated
administration there was signiﬁcantly reduced spasticity
compared with starting values 7 days earlier (Figure 2D;
n = 15 limbs from eight mice). However, spasticity returned
to baseline levels following cessation of treatment (resistance
to ﬂexion force baseline 0.174 ± 0.033 N) 2 weeks after
cessation of weekly VSN16R treatment (0.157 ± 0.045 N
[mean ± SEM] n = 10 limbs from six animals. Two animals
were reached humane endpoints after termination of
VSN16R dosing). Repeated daily vehicle failed to inﬂuence
the degree of spasticity (Figure 2E). However, in contrast to
the lack of desensitization with repeated VSN16R (Figure 2D),
repeated 5 mg·kg1 p.o. baclofen (GABAB agonist, Figure 2E)
and 25 mg·kg1 s.c. CNQX (AMPA/kainate glutamate receptor
antagonist, Figure 2F) showed inhibitory responses that
diminished over time (Figure 2E, F). This was indicative of
receptor desensitization and supports the need to dose-escalate
baclofen when used in humans (Shakespeare et al., 2003).
Furthermore, in contrast to the loss of muscle tone in healthy
animals that can occur following sedation (Supporting
Information Figure S3), 40 mg·kg1 p.o. caused no signiﬁcant
loss of muscle tone in normal animals [9.1 ± 6.3% change (in-
crease) from baseline n = 6 animals compared with a signiﬁcant
17.8 ± 5.3% drop (n = 8 animals; compared with baseline using
repeated measures ANOVA) in visibly spastic animals]. In this
analysis (Figure 2A–F), each limb was treated as the unit of
assessment, to encompass the marked variability of spasticity
in different limbs (Figure 2B) and offers 3Rs value to limit
animal use (Baker et al., 2000). However, to address concerns
of pseudo-replication via analysis of both limbs, when only
one mean result per animal was assessed, again, 0.1 mL vehicle
failed to inﬂuence spasticity (P > 0.05, n = 17 animals) and
again, 5mg·kg1 p.o. signiﬁcantly (at 30min, 60min) inhibited
spasticity (n = 17 animals) when compared with baseline
(Figure 2G). Furthermore, whilst the mean group score (±SD)
in vehicle-treated animals (0.278 ± 0.078 N) was no different
from the baseline of animals treated with 5 mg·kg1 p.o.
(0.302 ± 0.073 N), animals were signiﬁcantly less spastic
30 min (0.224 ± 0.067 N) and 60 min (0.214 ± 0.071 N) follow-
ing treatment with 5 mg·kg1 p.o. compared with vehicle-
treated animals (Figure 2G).
The Hoffman (H) reﬂex, where the spinal reﬂex is highly
exaggerated due to over excitation/loss of descending inhibi-
tory tone following the CNS damage that causes spasticity
(Matthews, 1966; Baker et al., 2012) was assessed (Supporting
Information Figure S3). Although it is often used in experi-
mental spasticity studies (Modol et al., 2014), electrophysiol-
ogy may not always detect anti-spastic effects in humans and
does not always yield consistent results (Leocani et al., 2015).
Whilst the H reﬂex following stimulation of the sciatic nerve
and recording from the anterior tibialis muscle (Modol et al.,
2014) could be variably detected and modiﬁed by VSN16R
in some animals, this was not consistent (Supporting Infor-
mation Figure S3). Furthermore, this approach was consid-
ered of limited value as it was clear that the ketamine
(NMDA antagonist) and medetomidine/dexmedetomidine
hydrochloride (α2-adrenoceptor agonist) anaesthetics
typically used (Modol et al., 2014), inhibited physical
spasticity, and importantly, the anaesthetics were found to
block the mechanism of action of VSN16R (Supporting
Information Figure S3). Furthermore, the animals, which are
severely neurologically affected could not tolerate the anaes-
thetic procedure, unlike healthy mice, and it often caused
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Figure 2
Oral VSN16R inhibits spasticity. Inhibition of spasticity measured as the resistance to ﬂexion against a strain gauge in visibly spastic ABH mice
showing the force required for ﬂexion. Animals received p.o. (A) 0.5 mg·kg1 (n = 10 animals; n = 20 limbs), 1 mg·kg1 (n = 10 animals n = 18
limbs) or 5 mg·kg1 p.o. VSN16R in water (n = 10 animals, n = 19 limbs). (B) The change in resistance to ﬂexion forces of individual limbs from
baseline to 60 min following 5 mg·kg1 p.o. administration (n = 17 animals, n = 32 limbs). (C) Effect of 40 mg·kg1 VSN16R (n = 8 animals,
n = 15 limbs). (D) Repeated daily administration of 40 mg·kg1 with measurement on the ﬁrst and eighth day of treatment (n = 8 animals
n = 15 limbs). (E) Repeated daily administration of vehicle (n = 9, n = 18 limbs) or 5 mg·kg1 p.o. in baclofen in water (n = 7 animals, n = 14 limbs),
where there was no difference at baseline between days 0 and 7. (E) Repeated daily 25 mg·kg1 CNQX s.c. (n = 5 animals, n = 10 limbs). *Signif-
icantly different compared with baseline. (F) Comparison of 5 mg·kg1 p.o. VSN16R in water (n = 17 animals) and vehicle-treated animals (n = 17
animals) using a single mean combined from both limbs, rather than analysis of individual limbs. #Signiﬁcantly different compared with
vehicle-treated animals. (F) Plasma levels of VSN16R following p.o. delivery of 5mg·kg1 VSN16R to spastic ABHmice with EAE or 400mg VSN16R
(~5 mg·kg1) p.o. in healthy humans; n = 6.
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them to die. Therefore, the approach was terminated on eth-
ical grounds.
It was clear from pharmacokinetic studies in mice that
there was over 15% CNS penetration with VSN16R, even at
low doses (Figure 1F). Given the high doses of VSN16R that
could be administered, it was evident that brain penetration
of VSN16R was not inducing abnormal behavioural effects
(Supporting Information Table S1), consistent with the direct
CNS injection of VSN16R (Figure 1D). Furthermore, CNS pen-
etration is increased during spastic EAE, due to blood–brain
barrier dysfunction (Al-Izki et al., 2014). As such, a CNS-
excluded CB1 receptor agonist (10 mg·kg
1 i.v. CT3; Pryce
et al., 2014) induced signiﬁcant cannabimimetic effects in
spastic animals (2.3 ± 0.4°C temperature loss, 20 min after ad-
ministration, n = 6 mice) at doses that did not affect healthy
mice (0.0 ± 0.1°C, n = 5 mice). In addition, it was possible to
detect VSN16R in spinal cords of chronic EAE animals (brains
4/4 mice, spinals cords n = 2/4 mice) compared with normal
animals (brains n = 4/4 mice, spinal cords n = 0/4 mice), de-
spite the lack of sensitivity of the assay, indicating that there
is some additional lesional targeting of VSN16R during EAE,
as has been seen previously with other compounds that are
not fully CNS-penetrant (Al-Izki et al., 2014). The duration
of action showed a reasonably good correlation with the
pharmacodynamics of plasma levels of VSN16R in ABH mice
with EAE (Figure 2H). Similar plasma levels of drug could
easily be achieved and exceeded with comparable doses of
VSN16R in healthy humans (Figure 2F).
Metabolism of VSN16R produces biologically
active metabolites
Pharmacokinetic studies have indicated rapid absorption of
VSN16R in rodents (Figure 1F). Renal excretion accounted
for less than 0.5% of the dose administered, and faecal elimi-
nation was approximately 1% of the dose in the ﬁrst 12 h
following p.o. dosing of rats (n = 3). VSN16R was stable (t½
>100 min which was the upper limit for assessment) in liver
microsomes and plasma, compared with midazolam
(t½ = 17 min) in liver microsomes and bisacodyl (t½ = 2 min)
in plasma. VSN16R showed no signiﬁcant inhibition of
cytochrome p450 enzymes at 10 μM suggesting limited
potential for drug–drug interactions (Supporting
Information Table S2). However, when VSN16R was incu-
bated with mouse, rat, dog, monkey and human hepatocytes,
and the supernatants assessed by LC–MS 1 h later, two domi-
nant metabolites from mouse hepatocytes were identiﬁed
and synthesized (Figure 3A). (R,Z)-N-(1-hydroxypropan-2-
yl)-3-(6-(methylamino)-6-oxohex-1-en-1-yl)benzamide (mo-
lecular weight = 304 Da), named VSN22R, resulted from
demethylation of the N-dimethyl amino group of VSN16R.
Oxidation of the terminal alcohol group to form a carboxylic
acid produced (Z)-(3-(6-(dimethylamino)-6-oxohex-1-en-1-
yl)benzoyl)-D-alanine (molecular weight = 332 Da), which
was named VSN44R (Figure 3A). VSN22R and VSN44R were
tested in the electrically-evoked contraction assays of the
mouse vas deferens, and it was found that VSN22R had com-
parable afﬁnity (EC50 = 9 nM) to VSN16R (EC50 = 10 nM),
whereas VSN44Rwas signiﬁcantlymore potent (EC50 = 1 nM)
(Figure 3B). In contrast, they all had comparable activity
(EC50 = ~100 nM) in relaxing methoxamine-evoked
contraction of third-order mesenteric arteries (Figure 3C).
However, given the activity in the tissue-based assays
(Figure 3B, C), it was not surprising that both VSN22R and
VSN44R could inhibit the spasticity during EAE (Figure 3D).
This indicates that they should contribute to the pharmaco-
logical effect of VSN16R in vivo.
VSN16R is well tolerated at drug levels
achievable in humans
Studies indicated that mice tolerate 1000 mg·kg1 p.o. and
likewise, independent, toxicology studies indicated that the
no “evidence of adverse events level (NOEL)” was
1000mg·kg1 p.o. in rats over 28 days (n = 20). The NOEL
was 150 mg·kg1 p.o. in rabbits and 100 mg·kg1 p.o. in dogs
(n = 6) with reproductive toxicology safe levels at
1000mg·kg1 p.o. in rats (n = 9) and >500 mg·kg1 in rabbits
(n = 9), and there was no evidence of mutagenesis in a stan-
dard Ames test (Supporting Information Table S3). In rats,
there was occasional salivation and ‘ploughing’ behaviours,
and there was salivation and vomiting in dogs at doses of
200mg·kg1 p.o. Likewise, rabbits demonstrated loss of appe-
tite and loss of weight at higher (>150 mg·kg1) doses of
VSN16R. These behaviours can be associated with poor taste.
This aspect was avoided by encapsulating the drug for human
use and no vomiting or issues of taste were reported in human
studies (n = 60). Histological analysis of animal (>30) tissues
showed essentially no signiﬁcant microscopic ﬁndings attrib-
utable to VSN16R (Supporting Information Table S4), and
there were no cardiovascular issues (Supporting
Information Table S5). The drug was therefore very well toler-
ated in animals. Analysis of plasma levels of a therapeutic
5mg·kg1 p.o. dose of VSN16R in ABH mice with spastic
EAE indicated that there was only 73.0 ± 6.1 ng·mL1 of
VSN16R, 106 ± 6.1 ng·mL1 VSN22R and only 2.1 ±0.3ng·mL1
VSN44R present (n = 4). This plasma level of VSN16R and its
metabolites was easily achievable in rats (Figure 4A) and dogs
(Figure 4B) in toxicological studies and safety studies in
humans (Figure 4C, D). Thirty minutes following 50 mg·kg1
p.o., the amount of VSN16R detected in plasma (Mean ± SD)
was 4907 ± 32.3 ng·mL1 (15 μM) in rats (n = 6) compared with
26 150 ± 1557 ng·mL1 (82 μM) in dogs (n = 6). At Cmax,
typically at 30 min following 1000 mg·kg1 p.o., there was
up to 117 000 ± 5710 ng·mL1 (368 μM) VSN16R in rats
(n=8),andat200mg·kg1p.o., therewas105283±13309ng·mL1
VSN16R in dogs (n = 6), and therefore, animals could tolerate
high levels of VSN16R.
VSN16R is well tolerated in humans
Healthy male volunteers 18–50 years old (Supporting
Information Table S6) were randomly allocated to treatment
in double-blind, placebo-controlled, phase I studies (EudraCT
2013-002765-18). This consisted of a single ascending dose
(SAD) study of 25, 50, 100, 200, 400 and 800 mg in groups
of eight different people per dose with six people given active
drug in either 25 or 100 mg gelatine capsules (Figure 4C). No
serious adverse drug-related events occurred, and treatment
was largely unremarkable in all cases. Any adverse events re-
ported (14.3% in SAD) were mild, and none were considered
to be deﬁnitively related to VSN16R, although no adverse
event was recorded in people treated with placebo capsules.
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However, 5/42 VSN16R-treated subjects (11.9%) were consid-
ered to have a possible associated effect with treatment; these
included dizziness (one subject at 25 and 50 mg), headache
(one subject at 200 mg) and dyspepsia and nausea (at
800 mg). Haematology and serum biochemistry (Supporting
Information Table S7), coagulation, urine analysis, vital signs
and electrocardiograms (Supporting Information Table S8)
and blood pressure (10 min in a supine position or after
1 min standing; Supporting Information Table S9) remained
unremarkable. Plasma was repeatedly sampled, and pharma-
cokinetic studies demonstrated the rapid presence of VSN16R
indicating good gut absorption, with 100% bioavailability at
25 mg and a terminal elimination of 3.4–4.9 h over the dose
range studied (Figure 4C). Even at the lowest drug dose tested
(25mg), it was clear that plasma levels were well above plasma
levels of therapeutic 5 mg·kg1 p.o. doses in mice, and
these were achieved for a number of hours (Figure 4C, D).
Formation of metabolites was rapid, and it was found that
VSN22R was the dominant metabolite species in humans
and once generated levels were similar to those found with
VSN16R and had a terminal elimination half-life of
4.0–5.3 h across the dose range tested (Figure 4A–C).
Again VSN44R appeared at 10- to 100-fold lower levels
(Figure 4A–C). These data suggest that even in the absence
of a slow-release formulation, twice (b.i.d)-thrice daily drug
delivery could probably achieve steady state, therapeutic
drug levels (Figure 4F). In addition to the trial containing
a multiple ascending drug dose study of twice daily 25,
100 and 400 mg in groups of eight different fasted people
per dose, six people were given the active drug at doses of
either 25 or 100 mg in gelatine capsules (Figure 4D). Again,
the drug was well tolerated and the pharmacokinetics
Figure 3
VSN16R produces active metabolites. (A) VSN16R was incubated with primary mouse rat, monkey and human hepatocytes and, 1 h later, the su-
pernatants were assessed by liquid crystallography mass spectroscopy and two species, VSN22R and VSN44R, were identiﬁed, and the results
expressed as percentage of the original starting material. Inset shows the structure of VSN22R and VSN44R. (B) Inhibition of electrically-evoked
contraction of the mouse vas deferens following incubation with various doses of VSN22R and VSN44R (n = 5 replicates). (C) VSN16R (n = 8 cul-
tures), VSN22R (n = 6 cultures), VSN44R (n = 8 cultures)-mediated relaxation of methoxamine-evoked contraction in rat mesenteric arteries. (D)
Inhibition of spasticity measured as the resistance to hindlimb ﬂexion against a strain gauge in visibly spastic ABH mice, showing mean ± SEM fol-
lowing injection of 5 mg·kg1 i.v. VSN16R (n = 7 animals, n = 14 limbs), VSN22R (n = 7 animals, n = 14 limbs) or VSN44R (n = 9 animals, n = 18
limbs). *Signiﬁcantly different compared with baseline.
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Figure 4
Pharmacokinetics of VSN16R in rats, dogs and humans. Liquid chromatography mass spectrometry plasma levels of VSN16R, VSN22R or VSN44R
detected in (A) rat after 5 mg·kg1 or 50 mg·kg1 VSN16R p.o. (n = 6 per group) and (B) dogs after 50 mg·kg1 p.o. (n = 6). (C) Human VSN16R
levels after 25, 50, 100, 200, 400 and 800 mg p.o.; (D) human VSN16R, VSN22R and VSN44R levels after 25 and 800 mg VSN16R p.o. (n = 6 sub-
jects per group). (E) Human VSN16R, VSN22R and VSN44R plasma levels after twice daily 400 mg VSN16R p.o., where the 12 h sample was taken
immediately before dosing (n = 6 humans per group). (F) Human VSN16R, VSN22R and VSN44R plasma levels after 200mg VSN16R p.o. in people
that were fed or fasted before drug administration.
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resembled that following the SAD studies (Figure 4C–E). It
was found that 6/18 VSN16R-treated subjects (33.3%) and
to 2/6 (33.3%) placebo subjects reported adverse events
and 3/18 VSN16R-treated subjects (16.7%) were consid-
ered to have a possible side effect of the treatment, al-
though again none was considered to be deﬁnitely
related to drug treatment. These people reported
oropharngeal pain and rhinitis (at 25 mg b.i.d), abdomi-
nal distension (at 25 mg b.i.d) and abdominal pain and
nausea (at 400 mg b.i.d). There were no serious adverse
events. Following twice daily dosing, steady-state plasma
levels above 100 nM for both VSN16R and VSN22R, likely
to be therapeutic, could be achieved in healthy individ-
uals (Figure 4D). Initial studies were in fasted individuals
(Figure 4C–E), and therefore, studies were undertaken fol-
lowing feeding with 0.5 h of dosing. Whilst this delayed
the time of the Cmax (Tmax) and reduced Cmax, the extent
of absorption (total exposures) was not inﬂuenced and if
anything, feeding improved the therapeutic levels of
VSN16R and its metabolites (Figure 4F). These data indi-
cate that VSN16R is well tolerated in humans and does
not induce sedation.
VSN16R targets BKCa potassium channels
independently of G-protein-coupled
cannabinoid receptors
VSN16R was shown to be a safe and potent anti-spastic agent,
but its mechanism of action was not initially obvious, as early
in the studies it was recognized that, despite being antago-
nized by SR141716A (Figure 1A), it does not bind to or ag-
onize CB1 receptors in receptor-transfected cell line-based
assays (Supporting Information Figure S5). Furthermore,
VSN16 could still signiﬁcantly inhibit spasticity in global
CB1 receptor-deﬁcient ABH mice (Figure 5A). Therefore,
the action of VSN16R was clearly independent of CB1
receptors. In addition, VSN16R did not bind (tested to
10 μM) to CB2 receptors or other parts of the
endocannabinoid and endovanilloid system (tested to
10 μM) and a wide range of receptors and transporters
(Supporting Information Figure S5).
Although SR141716A and AM251 are CB1 receptor antag-
onists, they have additional off-target effects associated with
a non CB1/CB2 receptor vascular target of anandamide (Ho
and Randall, 2007; Pertwee et al., 2010). These compounds
and O-1918 antagonize the action of VSN16R in mesenteric
artery relaxation assays (Hoi et al., 2007), and these effects
were used to help identify the target for VSN16R activity. It
has been reported that O-1918 can target GPR18 and
GPR55, candidates for a putative non-CB1/CB2 vascular can-
nabinoid receptor that is activated by some
endocannabinoids (Baker et al., 2006; McHugh et al., 2010;
Bondarenko, 2014). Stimulation of this vascular target has
been associated with the development of low blood pressure
in some studies (Bondarenko, 2014); however, it was clear
that VSN16R did not induce hypotension in rodents (Hoi
et al., 2007), dogs and humans (Supporting Information-
Tables 5S and S9). GPR18 and notably GPR55 are bound by
SR141716A and AM251 (Baker et al., 2006; Pertwee et al.,
2010). However, as the action of VSN16R is Bordetella pertussis
toxin-insensitive, the vasorelaxing effect of VSN16R is not
mediated by GPR18 (Hoi et al., 2007). Furthermore, VSN16R
does not directly bind to GPR55 either [tested in Multispan
C1113, Multispan H113, HEK293T.GPR55 cells lines and
mouse DBT.Gpr55 cell lines in a variety of different assays in-
cluding calcium signalling, receptor internalization and nu-
clear localization of cAMP response element binding protein
(Supporting Information Figure S5)]. Importantly, VSN16R
continued to inhibit spasticity in GPR55-deﬁcient ABH mice
(Figure 5B). Therefore, other O-1918 reactive targets were
examined.
Although VSN16 was originally designed as an ananda-
mide analogue, it is also structurally similar to N-
arachidonoyl glycine and N-arachidonoyl serine
(Supporting Information Figure S1). Arachidonoyl glycine
is an endogenous ligand of GPR18 that causes vasorelax-
ation, which is blocked by O-1918, via stimulation of a pre-
sumed G-protein-coupled vascular receptor (Parmar and Ho,
2010). However, this appears to directly activate big con-
ductance calcium-activated potassium (BKCa) channels
(Bondarenko et al., 2013). Likewise, N-arachidonoyl serine
that may act on GPR55 can inhibit vasorelaxation by endo-
thelial cell-dependent and independent mechanisms
following direct BKCa activity that was directly blocked by
O-1918 (Godlewski et al., 2009). This suggested that BKCa
channels may mediate the vasorelaxing effects of at least
some cannabinoids (Bondarenko, 2014). VSN16R had no ef-
fects on the primary porcine aorta endothelium (Supporting
Information Figure S4), but in assays in third-order rat mes-
enteric arteries, VSN16R induce signiﬁcant vasorelaxation
in an endothelium-dependent manner (Figure 5C) and this
effect was signiﬁcantly inhibited by antagonists of BKCa
channels, notably by iberotoxin and charybdotoxin.
Apamin, a KCa2.2/2.3 (KCNN2/KCNN3) channel
antagonist, alone had a small inhibitory effect on VSN16R
function in the mesenteric artery assay (Figure 5D), but
VSN16R failed to block the binding of apamin to KCa2.2
channels in transfected cells (Supporting Information Figure S5).
In addition, the relaxation was dependent on potassium ﬂux,
as VSN16R produced no relaxation in the presence of extracel-
lular 60 mM KCl, supporting an action via BKCa channels
(Figure 5C).
This target was deﬁnitively shown in single channel,
inside-out patch clamp experiments in human EA.hy926
cells (Bondarenko et al., 2011), where VSN16R (n = 17
patches), VSN22R (n = 22 patches) and VSN44R (n = 4
patches) all facilitated single BKCa channel activity when ap-
plied to the inner surface of the membrane (Figure 5E). The
increase in NPo occurred in a concentration-, calcium- and
voltage-dependent manner (Figures 5F, G; Supporting
Information Figure S3), indicating that the compounds di-
rectly act as BKCa channel openers, without binding to other
receptors; this causes hyperpolarization of the membrane.
Importantly, this mechanism was active in human HCN-2
neural cells where VSN16R stimulated single BKCa channel
activity in inside-out patches (Figure 5H), providing further
evidence that VSN16R acts directly via neuronal BKCa chan-
nels (Figure 5H). Consistent with this, RNAseq indicated that
EA.hy926 cells essentially only express the neural, KCNMA1,
KCNMB4 BKCa isoform (Figure 6A). They did not express
any of the leucine-rich repeats containing BKCa γ
subunit proteins (Zhang and Yan, 2014) or the STREX
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Figure 5
VSN16R is a BKCa channel opener. (A) Percentage change in resistance to ﬂexion in response to treatment with either 1 mg·kg
1 i.p. CP55,950
(n = 5 animals, n = 8 limbs), 5 mg·kg1 i.p. R(+)WIN55,212 (n = 7 animals, n = 14 limbs) or 5 mg·kg1 i.v. VSN16R in wild-type ABH (n = 7 animals,
n = 14 limbs) or congenic CB1 receptor-deﬁcient mice (n = 5 animals per group n = 10 limbs) at 30 min after treatment. (B) Changes in resistance
to ﬂexion in response to treatment with vehicle (n = 8 animals, n = 14 limbs) or 10 mg·kg1 i.v. VSN16R wild-type ABH (n = 8 animals, n = 16 limbs)
or congenic GPR55-deﬁcient mice (n = 8 animals, n = 15 limbs). (C, D) Dose-dependent VSN16R-mediated relaxation of methoxamine-evoked
contractions in rat mesenteric arteries. (C) Endothelial intact (n = 11 assays), endothelium denuded (n = 6 assays) or endothelium intact cultures
in the presence of 60 mM KCl (n = 4 assays). (D) Vehicle-treated controls (n = 17 assays) or pretreated with 50 nM apamin (n = 7 assays), 50 nM
iberotoxin (n = 5 assays), 50 nM charybdotoxin (n = 6 assays) or a combination of apamin and charybdotoxin (n = 6 assays). (E) At 3 μM VSN16R,
VSN22R and VSN44R stimulate single BKCa channel activity in inside-out patches, excised from EA.hy926 cells, held at 40 mV and exposed to
0.3 μM free Ca2+; representative plots are shown. (F, G) Statistical representation of the potentiation of BKCa single channel activity (NPo) by
3 μM VSN16R. (F) Concentration-dependent increase in NPo by 0.3–30 μM VSN16R at a holding voltage of 60 mV and (G) different voltages
and ﬁxed Ca2+ 300 nM. The number of patches is shown in brackets. The results represent the mean ± SD. (H) VSN16R stimulates single BKCa
channel activity in inside-out patch excised from human neural HCN-2 cells and held at either 20 or 40 mV in the presence of 0.3 μM free Ca2+
(n = 4 patches).
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Figure 6
BKCa openers control spasticity. (A) RNAseq expression of BKCa channel components in EA.hy926 cells. Inset represents the western blot of
KCNMB4 in EA.hy926 cells, which was tested in four samples, and western blot of KCNMB4 expression in the spinal cord in control (n = 3) and
spastic EAE spinal cord tissues (two shown, n = 6 total) showing an additional prominent band, not present in EA.hy926 cells, above the
anticipated fragment size more notable during EAE. This antibody detected multiple bands in western blot analyses. (B) RNAseq expression of
BKCa channel components in the spinal cords of spastic EAE (n = 3 mice) and age-matched normal mice (n = 3 mice). The results represent the
mean ± SD. Inset represents the western blot of KCNMA1 in control and spastic EAE tissue (Antibody APC-021 detected a single band at the
anticipated size and was repeated with antibody APC-151 with comparable results), and insets show a signiﬁcant change in ratio between Kcnma1
and neuroﬁlament light (Neﬂ) gene levels. (C) Percentage change in resistance to ﬂexion of spastic hindlimbs in ABHmice in response to treatment
with 5 mg·kg1 p.o. VSN16R in water (n = 10 animals, n = 19 limbs) that were pretreated with saline or 1 mg·kg1 i.p. paxilline (n = 7 animals,
n = 14 limbs). (D) Percentage change in resistance to ﬂexion of hindlimbs in ABH mice following injection i.p. with 1 mg·kg1 paxilline (n = 7
animals, n = 13 limbs), 40 mg·kg1 i.p. BMS-204352 (n = 7 animals, n = 13 limbs), 20 mg·kg1 i.p. NS-1619 (n = 7 animals, n = 14 limbs)
or 10 mg·kg1 i.p. NS-11021 (n = 7 animals, n = 13 limbs). *Signiﬁcant difference compared with baseline.
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(Xie and McCobb, 1998) steroid-responsive KCNMA1
splice variant (Figure 6A).
BKCa channels are dysregulated during EAE and
are a novel mechanism to control spasticity
In the spinal cord, the dominant BKCa subunits are the
KCNMA1 α pore and the KCNMB4 β chain, and KCNMB2 to
a lesser extent and the LRRC52 γ chain (Figure 6B). Surpris-
ingly, RNAseq analysis of spinal cords from spastic and
age-matched controls (n = 3) failed to detect signiﬁcant differ-
ences in the expression of any of the BKCa subunits (Figure 6
B), consistent with KCNMA1-speciﬁc western blot of spinal
cords (Figure 6B). Likewise, western blot of KCNMB4 in spinal
cords did not indicate differences of KCNMB4 levels in spastic
EAE, although additional bands, not present in EAE.hy926,
became prominent in spastic mice with EAE (n = 6) compared
with controls (n = 3), possibly due to disease-related post-
translational modiﬁcations (Figure 6A), such as glycosylation
(Jin et al., 2002). However, as spastic EAE is associated with
signiﬁcant nerve loss (Pryce et al., 2003), when KCNMA1
expression was normalized to neuroﬁlament content, there
was a signiﬁcant increase in the KCNMA1 (Kcnma1) to neuro-
ﬁlament light (Nefl) ratio in spastic mice (Figure 6B), suggest-
ing some dysregulation during the disease. However,
blockade of the receptor with paxilline did not inﬂuence the
baseline level of spasticity (Figure 6C, D). Animals with a
deﬁciency in BKCa channels can exhibit adverse motor
phenotypes and abnormal development that prelude their
use in spasticity studies (Brenner et al., 2000; Sausbier et al.,
2004; Martinez-Espinosa et al., 2014); therefore, a pharmaco-
logical approach was used to investigate the involvement of
BKCa channels in the effects of VSN16R (Figure 6C). It was
found that 1 mg·kg1 i.p. of the BKCa antagonist paxilline,
which is just below a tremorogenic dose in mice (Imlach
et al., 2008), could completely inhibit the action of VSN16R
(Figure 6C). Furthermore, when structurally unrelated BKCa
openers were investigated in spasticity in EAE, it was found
that BMS-204352, NS-1619 and NS-11021, used at published
in vivo i.p. doses, could all signiﬁcantly inhibit spasticity
(Figure 6D), without causing sedation. These ﬁndings con-
ﬁrm that BKCa potassium channel openers could provide a
novel mechanism to control spasticity.
Discussion
This study demonstrates that neural BKCa channels are a pre-
viously unrecognized target for control of spasticity in MS
and other conditions. As such, compounds that support the
opening of the BKCa channels and hyperpolarize neural
membranes will limit neural excitability to control spasticity,
in the absence of sedating side effects. These could also po-
tentially affect and may be of value in the control of other
MS symptoms or other conditions associated with neural
hyperactivity and BKCa mutations: such as epilepsy, neuro-
pathic pain, tinnitus and fragile X syndrome (Sausbier et al.,
2004; Brenner et al., 2005; N’Gouemo, 2014; Liu et al.,
2015). The opening of calcium-activated potassium channels
forms part of the neuronal repolarizing mechanism that
helps reset the ionic balance of the nerve to facilitate the gen-
eration of further action potentials (Sausbier et al., 2004;
Brenner et al., 2005; N’Gouemo, 2014). The observed up-
regulation of these channels in spinal cords probably contrib-
utes to facilitating the overexcitation of motor nerves leading
to spasticity. As NS-1619, which is a KCNMA1-selective agent
(Gessner et al., 2012), can control spasticity, this indicates
that potassium-induced neural membrane hyperpolarization
following the opening of the α pore in BKCa channels is the
important mechanism of action of this compound. VSN16R
also induces a similar effect by this mechanism, which will
limit the generation of action potentials and control
spasticity.
Although VSN16R and NS-1619 both maintain the open-
ing of BKCa channels, via the KCNMA1 pore, to produce
membrane currents and both have their effects blocked by
the actions of iberotoxin and SR141617A (White and Hiley,
1998), they have subtly distinct pharmacology andmolecular
targets (White and Hiley, 1998; Begg et al., 2003; Hoi et al.,
2007; Gessner et al., 2012). NS-1619 opens BKCa via a direct ef-
fect on the KCNMA1 pore of the channel and does not re-
quire the presence of KCNMB β chains for activity (White
and Hiley, 1998; Gessner et al., 2012). Furthermore, in con-
trast to VSN16R, the action of NS-1619 is resistant to the an-
tagonistic effect of O-1918 (Gessner et al., 2012). As such,
NS-1619 relaxes mesenteric arteries via an additional,
endothelial-independent mechanism that is due to an action
on the KCNMA1 pore in smooth muscle that express the
KCNMA1, KCNMB1 BKCa isoform (White and Hiley, 1998;
Brenner et al., 2000; Papassotiriou et al., 2000; Sausbier et al.,
2004). VSN16R does not activate KCNMA1 directly or act
via the smooth muscle BKCa isoform, as we showed here that
its ability to induce arterial relaxation is endothelial cell-
dependent. Also VSN16R does not induce relaxation of por-
cine aorta that express low levels of KCNMA1 and no BKCa β
chains (Papassotiriou et al., 2000) and the lacks an effect on
βγ-methylene ATP activity in smooth muscle. This is consis-
tent with the lack of inﬂuence of VSN16R on blood pressure
observed in rats, dogs and humans, which is controlled by
KCNMA1 and KCNMB1 on smooth muscle (Brenner et al.,
2000; Sausbier et al., 2004; Zheng et al., 2013). Likewise,
VSN16R does not need the presence of BKCa γ chains for activ-
ity. Therefore, although the effects of VSN16R are associated
with membrane hyperpolarization that results from
KCNMA1 pore opening, maintaining the opening of the pore
must occur via interactions of other elements (KCNMB4) of
the BKCa channels. Skeletal muscles express only trace levels
of BKCa (KNCMA1) and do not appear to express KCNMB1-4
(Freeman et al., 1998; Bednarczyk et al., 2013) and are
therefore unlikely to be responsive to VSN16R. However, a
neuronal action of VSN16Rwas indicated via the electrophys-
iological control of spasticity and the ﬁnding that a VSN16R-
responsive cell line essentially only expresses a single
KCNMA/KCNMB4 BKCa channel, which is the major
neuronal BKCa isotype (Bednarczyk et al., 2013). Neuronal
BKCa channels are found at high levels within sensory nerves,
notably within dorsal root ganglia and spinal nerves (Allen
Spinal Cord Atlas, 2008; Freeman et al., 1998), where they
may affect motor nerves or inhibitory interneurons, with or
without inﬂuences on sensory outputs, as has been found
with cannabinoid receptor agonists (Pryce et al., 2014).
Further work is required to determine the precise location
and molecular function of VSN16R on BKCa channels during
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spasticity. However, this is complicated, as BKCa gene knock-
out animals exhibit adverse neurological phenotypes includ-
ing premature death, ataxia, tremors and gait and movement
problems, which preclude their use in spasticity in vivo
(Brenner et al., 2000; Sausbier et al., 2004).Nevertheless, this
may highlight new indications for treatment with VSN16R
or related molecules. Furthermore, the structural and electro-
physiological biology of BKCa channels is highly complex be-
cause of their multimeric structure of alternatively spliced
and post-translationally modiﬁed α, β and γ chains, which
modulate both the expression of the α chain and the calcium
and voltage thresholds of the α pore in both positive and neg-
ative ways (Brenner et al., 2000; Weiger et al., 2000; Sausbier
et al., 2004; Zhang and Yan, 2014). As such, both gain and
loss of function of the BKCa channels can lead to neural hy-
perexcitability (N’Gouemo, 2014). The BKCa channels also
appear to be part of the signalling machinery of some
cannabinoid-related GPCRs, such as GPR55 (Bondarenko
et al., 2011; Bondarenko, 2014) and potentially the CB1 recep-
tor (Sánchez-Pastor et al., 2014). In addition, being calcium-
dependent, BKCa channel activity and VSN16R function
may also be modulated secondary to alterations to intracellu-
lar calcium stimulation, or other intracellular signalling mol-
ecules, following activity of other receptors. This may be a
mechanism by which SR141617A can inhibit BKCa activity
in tissue assays (White and Hiley, 1998). This type of activity
may contribute to the confusion around the pharmacology
of endocannabinoids (Howlett et al., 2002; Pertwee et al.,
2010; Bondarenko, 2014). Additional actions of VSN16R
cannot be excluded, especially since anandamide has a
number of targets (Pertwee et al., 2010), but a large number
of relevant receptors and channels were excluded as poten-
tial targets. Importantly, the pharmacological action of
VSN16R was clearly blocked by antagonists of the BKCa
channel and demonstrates that this is a new target to
control spasticity.
This study indicates that potassium-induced hyperpolari-
zation following opening of the α pore in BKCa channels is a
novel central mechanism of action of these anti-spastic drugs
and, in neural membranes, will act to limit excessive action
potential generation. Such membrane hyperpolarization is
the common mechanism of action of many anti-spastic
agents, which counter excitatory depolarizing signals that
can lead to spasticity (Toda et al., 2014; Trompetto et al.,
2014). This pathway is mediated directly through the open-
ing of BKCa potassium channels, as shown here, and via cal-
cium channel inhibition and notably activation of inwardly
rectifying potassium channels after G protein signalling with
CB1 receptor and GABAB agonists, and through chloride ion
inﬂux following stimulation of GABAA receptors (Isomoto
et al., 1997; Howlett et al., 2002; Pertwee et al., 2010). How-
ever, in contrast to cannabinoids and GABA agonists,
VSN16R is well tolerated in animals, even following direct in-
jection into the brain. Likewise, BMS-204352, which is highly
hydrophobic and readily enters the brain, also has a large
therapeutic window in rodents (Gribkoff et al., 2001;
Kristensen et al., 2011). As BKCa channels are activated in
depolarizing conditions, it is possible that the BKCa channel
conformation targeted by VSN16R may only be active in cer-
tain states. As such, it is of interest that NS-1619 fails to inﬂu-
ence acute nociception but controls chronic neuropathic
pain (Chen et al., 2009), suggesting that the certain types of
BKCa channel may be pathologically expressed. This may
contribute to the lack of sedation observed here in both ani-
mals and humans. As the ﬁrst example of a neuronal-selective
BKCa channel ligand, VSN16Rmay be the prototype for a new
range of well-tolerated drugs with applications in diverse con-
ditions in which excitotoxicity is evident or where the chan-
nel has a speciﬁc role. VSN16R was originally designed as a
cyclic analogue of anandamide to exploit the beneﬁt that
the endocannabinoid system has to offer. Importantly,
however, it moves us away from the cannabis plant, and
all its issues of recreational use, towards a novel pharma-
ceutical class of agents that offers therapeutic beneﬁts with-
out the psychoactive effects associated with cannabis use
(Howlett et al., 2002; Varvel et al., 2005), or the sedating ef-
fects of other current anti-spastic agents (Shakespeare et al.,
2003). This suggests that VSN16R is ready for testing in
people with spasticity in MS (EudraCT 2014-004412-11,
NCT02542787) as a treatment for this neurological disease.
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Figure S1 Biological conformations of the arachidonic acid
chain. (A, B) “C” type conformations of the polyene chain
from diverse biological targets fromX-ray. This suggested that
conformational restriction of (C) anandamide would be use-
ful approach to generate novel molecules as in (D) VSN16.
This has structural similarities with (E) N-arachidonoyl gly-
cine and (F) N-arachidonoyl serine.
Figure S2 VSN16R does not inhibit β γ methylene adenosine
triphosphatase-induced muscle contraction in the vas deferens.
Mouse vas deferens were treated with either DMSO vehicle
or 100 nM VSN16R 30 min before the ﬁrst organ bath injec-
tion of various concentrations of βγ-methylene ATP into the
organ bath . The results represent the mean ± SEM of βγ-meth-
ylene ATP-induced increases in tension (expressed in grams)
of electrically unstimulated vasa deferentia. (n = 6/group).
Figure S3 Anaesthetics inhibit spasticity and muscle tone and
can interfere with the action of VSN16R. (A) Strain gauge record-
ing before and after (5 min) the induction of ketamine and
medetomide anaesthesia, typically used for rodent electro-
physiology studies. (B) Loss of muscle tone of spastic animals
following anaesthetic showing measurement of resistance to
limb ﬂexion before and 5min after anaesthesia.*** signiﬁcant
compared to baseline before anaesthetic using paired t-test
(n = 5 animals) (C) The magnitude of the H-wave was mea-
sured in the shin muscle in spastic animals following sciatic
nerve stimulation (100% = H wave at administration of
30 mg/kg i.v. VSN16R in PBS at 0 min). Although n = 0/3
PBS-treated animals showed an inhibition of the H reﬂex, this
could be inhibited by VSN16R (D) Electrophysiological trace
of the shin muscle following stimulation of a spastic mouse
before and after 30 mg/kg i.v. VSN16R administration. (E)
However, the H reﬂex was only inhibited in some (3/5) ani-
mals responded (Green circles), whereas others did not (blue
circles). Trace of individual mice (F) However, it was subse-
quently found that ketamine (200 μM. To represent anaes-
thetic levels in blood) can inhibit the mechanism of action
of VSN16R in part of the dose–response curve to
methoxamine-evoked contraction of rat mesenteric artery
(n = 5–6 cultures). Ketamine blocks NMDA receptors, that
limits calcium ion ﬂuxes that can inﬂuence BKCa function
and can inhibit the inside-out current of BKCa channels with
an EC50 = ~25 μM (Denson DD et al. Brain Res 638:61). In con-
trast to healthy animals, mice with spasticity did not tolerate
anaesthetics, which caused death in some instances,
prompting discontinuation of the approach prior to
attempted dose reduction.
Figure S4 Patch Clamp analysis of VSN16R activity on BKCa
channels. (A) Primary pig aorta do not respond to VSN16R
(n = 3 patches). Time course of the current development at
100 mV (lower) and +85 mV (upper) in response to VSN16R
or the removal of potassium. (B) Whole cell currents of hu-
man EA.hy926 cells in response to voltage ramps before (con-
trol), and during exposure to 15 μM VSN16R in the absence
and presence of 2 μMpaxilline. The current represents the in-
ﬂuence of endogenously expressed conducting ion channels
within the cell, but the sensitivity to paxilline indicates that
the majority response was mediated by BKca channels.
(C-E) This was shown in single channel patch clamp experi-
ments in EA.hy926 cells. (C) Voltage dependence of activity
of VSN16R in inside-out patch clamp of single BKCa channels
VSN16R. (D) Calcium dependence of activity of VSN16R. Sin-
gle BKCa channel activity in inside-out patch held at +60 mV
and exposed to either 1 μM or 0.3 μM free Ca2+ concentra-
tions before (control) and after treatment with 3 μMVSN16R.
(E) VSN16R exhibits a concentration-dependent induction of
potassium currents in inside-out patch clamp of single BKCa
in EA.hy926 cells. The patch was held at 20 mV and exposed
to 0.3 μM free Ca2+ under symmetrical K+ conditions. Repre-
sentative traces that were repeated.
Figure S5 Receptors and other targets that VSN16R fails to
bind/activate (A) Receptors lacking activity with 10 μM
VSN16R. Binding assays and positive controls were performed
by Cerep, Multispan, DiscoverX, MDS pharma and Chantest.
(B) Lack of activity of VSN16R on CB1 and CB2 cannabinoid re-
ceptors (C) Relative lack of activity of VSN16R agonism on
U20S cells transfected with human GPR119 compared with
oleoylethanolamide as assessed using cyclic AMP assay (D).
HEK293 cells do not respond to lysophosphoinositol (LPI.
GPR55 agonist) stimulation, but respond to lysophophatidic
acid (LPA), unless they are transfectedwith humanGPR55 (left)
as assessed using calcium ion ﬂuxes (Henstridge CM et al. Br J
Pharmacol 2010; 160:604). (E) HEK293.GPR55 demonstrate
calcium ﬂuxes following stimulation with AM251 but do not
respond to VSN16R (F) Lack of activity of VSN16R on DBT cells
stably transfected with mouse Gpr55. These were incubated
with 1-3 μM LPI, 10 μMVSN16A or the 10 μM and the nuclear
expression of cAMP response element-binding protein (CREB)
was assessed by immunocytochemistry (Henstridge et al. 2010).
Table S1 VSN16R does not induce neurobehavioural behavioural
tests in an Irwin test.
Table S2 VSN16R does not induce cytochrome P450 enzymes.
Table S3 VSN16R does not induce chromosomal mutagenesis.
Table S4 VSN16R does not induce tissue toxicology of VSN16R
in rats and dogs.
Table S5 Lack of hypotension induced by VSN16R in dogs.
Table S6 Demographics of humans in phase I double-blind, pla-
cebo-controlled trial.
Table S7 Single Dose of VSN16R did not affect haematology and
blood chemistry in humans.
Table S8 Single dose of VSN16R did not affect coagulation,
urinanalysis, vital signs and electrocardiograms in humans.
Table S9 Lack of hypotension induced by VSN16R in humans.
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